^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD1 inhibitor

    Related drugs:
    23h
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=97, Recruiting, Boehringer Ingelheim | N=70 --> 97
    Enrollment change
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    23h
    A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Tongji Hospital
    New P2 trial
    |
    cisplatin • Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)
    23h
    Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma (clinicaltrials.gov)
    P1/2, N=188, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P1/2 trial
    23h
    INTerpath-13: A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov)
    P2, N=180, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    24h
    Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung). (PubMed, Eur J Cancer)
    Short course preoperative nivolumab with or without relatlimab showed encouraging efficacy and survival outcomes, which compare favorably with chemo-immunotherapy-based perioperative treatment regimens.
    Journal
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    24h
    Efficacy and Safety of Different Treatment Regimens for Previously Untreated Patients with HER2-positive Advanced Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials. (PubMed, J Gastrointest Cancer)
    No first-line regimen significantly improved OS or PFS in HER2-positive advanced gastric cancer. However, HLX22-based and immune-combination strategies show potential clinical value-particularly in enhancing ORR-and merit further investigation.
    Clinical • Retrospective data • Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Hercessi (trastuzumab-strf)
    1d
    Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a review. (PubMed, Jpn J Clin Oncol)
    For instance, a recent phase II study of nivolumab rechallenge in non-small cell lung cancer patients who relapsed after an initial response reported a modest ORR of 8.5%...Although major guidelines recommend permanent discontinuation for severe (Grade ≥ 3) irAEs, emerging evidence-including class-switching strategies and organ-specific prophylaxis-suggests that rechallenge may be feasible in selected patients. A personalized risk-benefit assessment remains essential, considering the type and severity of the initial irAE and the reason for discontinuation.
    Journal • Adverse events • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab)
    1d
    Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design. (PubMed, Future Oncol)
    Approximately 714 patients will be randomized 1:1. The dual primary endpoints are progression-free survival as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors v1.1 and overall survival; secondary endpoints include additional efficacy, safety and tolerability, pharmacokinetics, and immunogenicity endpoints.Clinical trial registration: NCT06758401 (https://clinicaltrials.gov/study/NCT06758401).
    P3 data • Journal • Tumor proportion score • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • sigvotatug vedotin (PF-08046047)
    2d
    - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases (clinicaltrials.gov)
    P2, N=140, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting --> Recruiting | Initiation date: Apr 2025 --> Oct 2025
    Enrollment open • Trial initiation date • Mismatch repair • pMMR
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    2d
    Myocarditis induced by a novel bifunctional PD-1/CTLA-4 combination antibody: a case report and literature review. (PubMed, BMC Cardiovasc Disord)
    We report the first documented case of myocarditis linked to the novel bifunctional PD-1/CTLA-4 combination, Iparomlimab and Tuvonralimab. This case highlights that structural drug optimizations do not preclude severe cardiotoxicity. In resource-limited settings lacking advanced imaging, serial high-sensitivity troponin monitoring served as the cornerstone for early detection and guiding management. This experience confirms that favorable outcomes are achievable through vigilant biomarker surveillance and coordinated multidisciplinary care, even without advanced diagnostics.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • ICOS (Inducible T Cell Costimulator)
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    2d
    Pembrolizumab in Neoplasms or Lymphomas (clinicaltrials.gov)
    P2, N=18, Suspended, Dana-Farber Cancer Institute | Trial completion date: Aug 2025 --> Mar 2026
    Trial completion date
    |
    Keytruda (pembrolizumab)
    2d
    Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, University of Colorado, Denver | N=36 --> 19 | Trial primary completion date: Dec 2025 --> Jun 2025
    Enrollment change • Trial primary completion date • Checkpoint inhibition
    |
    Opdivo (nivolumab)